Tricky Testing in the Patient on Hemodialysis
2023 Advances in Peritoneal Dialysis Annual Symposium (Hybrid): Friday 9/29, Free for Trainees
Cylindroids in Urine, Have You Ever Seen It?
Midwest Transplant Symposium: October 13-15 (Travel Grants Available!)
Free Thrombotic Microangiopathy Workshop During Kidney Week
Scraping the Bottom of the Barrel in Patients with Exhausted Vascular Access: Unconventional Sites for Hemodialysis Arteriovenous Access Creation and Catheter Placement
Pericardial effusion detected on point of care ultrasound: What next?
Shared Decision Making in Dialysis Vascular Access
UAB CRRT Academy Information!
Landmark Trials on the use of Rituximab in ANCA Associated Vasculitis
Post by: Namrata Parikh. Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a group of autoimmune disorders whose hallmark is inflammation of small blood vessels throughout the body, producing a myriad of manifestations. AAV had once been considered to…
The Changing Tides of Immunosuppression
Post by: Aimen Liaqat, MD Nephrology Fellow, Cleveland Clinic We have come far since the first successful kidney transplant in 1954 when Ronald Herrick donated a kidney to his twin brother Richard at the Brigham and Women’s Hospital in Boston. This…
Ultrafiltration for Heart Failure
The concept of removing excess fluid via ultrafiltration (UF) is not a new one. The first described use of UF dates back to 1974. Back then, drip clamps were used to calibrate the amount of UF. For this…
Who is afraid of Osmotic Demyelination Syndrome? Severe hyponatremia – its limits, goals and clamps
From the early physiology courses in Medical School, everyone learns to be wary of rapidly correcting serum sodium in the event of hyponatremia if its duration is chronic or unknown. But was this concern always present? In the…
Landmark Nephrology: Use of Rituximab in Lupus Nephritis
Systemic lupus erythematosus (SLE) is an autoimmune disease with multisystem involvement and no cure. Among patients with SLE, roughly 50% develop lupus nephritis and are at risk of developing lupus nephritis-related end-stage kidney disease (ESKD). Current therapies for…
Landmark Trials in Anemia & Kidney Disease
As nephrologists, we remember the not so distant past when there were few options available to help patients battle the debilitating effects of anemia of chronic kidney disease. Fortunately, advances over the past two decades have led to…
Landmark Trials in Membranous Nephropathy
Membranous nephropathy (MN) is the most common cause of nephrotic syndrome in the Caucasian adult population with an estimated incidence of 8–10 cases per 1 million and commonly seen in males above the age of 40. It is…
Landmark Nephrology: Renal Replacement Therapy (RRT) Timing in Critically Ill Patients
Currently, the timing of initiation of renal replacement therapy (RRT) in critically ill patients with acute kidney injury (AKI) remains a challenge. T Despite several randomized controlled trials (RCTs) comparing early versus late initiation strategies of RRT, the…
Landmark Trials of Belatacept in Kidney Transplantation
The last few decades have been revolutionary in terms of improving end stage kidney disease (ESKD) care with respect to increasing the number of transplant recipients as well as upping the immunosuppression game. The use of calcineurin inhibitors…
Landmark Trials in Peritoneal Dialysis Adequacy: A 3-Minute Read
Peritoneal dialysis (PD) treatment began much earlier than hemodialysis but was not successful due to the many complications associated with it and the difficulties with access to the peritoneal cavity. It was in 1946 that Dr. Fine and…